Portal de investigación
FI19/00153 (PFIS) CARLOS VILLARROEL (209/207): CONTRATOS PREDOCTORALES DE FORMACIÓN EN INVESTIGACIÓN EN SALUD. Acción Estratégica en Salud 2019.
Datos básicos
- Protocolo:
- FI19/00153
- EUDRACT:
- NCT:
- Centro:
- INCLIVA-HOSPITAL CLÍNICO UNIVERSITARIO DE VALENCIA
- Año de incio:
- Año de finalización:
- 2023
Documentos
- No hay documentos
Participantes
Grupos y Plataformas de I+D+i
Financiadores - Promotores
INSTITUTO SALUD CARLOS III
Resultados del Ensayo Clínico
Benzopyran hydrazones with dual PPARa/? or PPARa/d agonism and an anti-inflammatory effect on human THP-1 macrophages.
Article. 10.1016/j.ejmech.2024.116125. 2024
Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: An overview.
Villarroel-Vicente, Carlos; (...); Cabedo, Nuria
Article. 10.1016/j.ejmech.2021.113535. 2021
Synthesis and biological studies of "Polycerasoidol" and "trans-d-Tocotrienolic acid" derivatives as PPARa and/or PPAR? agonists.
Vila, Laura; (...); Cortes, Diego
Article. 10.1016/j.bmc.2021.116532. 2022
Synthesis of 2-aminopropyl benzopyran derivatives as potential agents against triple-negative breast cancer
Article. 10.1039/d3md00385j. 2023
Synthesis of 2-Prenylated Alkoxylated Benzopyrans by Horner-Wadsworth-Emmons Olefination with PPARa/? Agonist Activity.
Garcia, A; (...); Cortes, D
Article. 10.1021/acsmedchemlett.1c00400. 2021
Synthesis of a new 2-prenylated quinoline as potential drug for metabolic syndrome with pan-PPAR activity and anti-inflammatory effects.
Villarroel-Vicente, C; (...); Cabedo, N
Article. 10.1016/j.bmcl.2024.129770. 2024
